Table 2.

Patient characteristics

Characteristic	Number of patients	Percentage (N = 65)
Age (years) at first stereotactic radiosurgery (SRS): median 61.5 [range 22–85]
Gender
Female	30	46.2%
Male	35	53.8%
Karnofsky performance status (KPS) at first SRS (median 90)
50	1	1.5%
60	3	4.6%
70–80	25	38.5%
90–100	36	55.4%
Graded prognostic assessment (GPA) score at first SRS (median 2)
1–1.5	16	24.6%
2–2.5	35	53.8%
3–3.5	11	16.9%
4	1	1.5%
Unknown	2	3.1%
Recursive partitioning analysis (RPA) score at first SRS (median II)
I	22	33.80%
II	40	61.50%
III	3	4.60%
Tumor entity of primary tumor
Adenocarcinoma lung	34	52.3%
Neuroendocrine carcinoma lung	4	6.2%
Squamous cell carcinoma lung	2	3.1%
Breast cancer	7	10.8%
Malignant melanoma	10	15.4%
Renal cell cancer	4	6.2%
Colon cancer	1	1.50%
Stomach cancer	1	1.50%
Uterine sarcoma	1	1.50%
Salivary gland carcinoma	1	1.50%
Median follow up time 13 months (95% CI 11.1–14.9)
Therapy following intracranial progression (N = 18)
Second SRS	9	13.8%
Third SRS	1	1.5%
WBRT	8	12.3%
Best supportive care	2	1.5%
Cerebral metastases per patient (median 3)
2	18	27.7%
3	19	29.2%
4	9	13.8%
5	9	13.8%
6	3	4.6%
7	2	3.1%
8	2	3.1%
9	0	0.0%
10	2	3.1%
11	0	0.0%
12	1	1.5%
Immunotherapy/targeted therapy (38 patients)
Pembrolizumab	17	26.2%
Nivolumab	12	18.5%
Bevacizumab	4	6.2%
Durvalumab	2	3.1%
Atezolizumab	1	1.5%
Ramucirumab	1	1.5%
Nivolumab/Ipilimumab	6	9.2%
Trastuzumab/pertuzumab	1	1.5%
Small molecules (14 patients)
Afatinib	4	6.2%
Osimertinib	3	4.6%
Axitinib	1	1.5%
Palbociclib	1	1.5%
Cabozantinib	1	1.5%
Sunitinib	1	1.5%
Dabrafenib/trametinib	5	7.7%
Binimetinib/encorafenib	1	1.5%
Crizotinib/alectinib	1	1.5%
Crizotinib/afatinib	1	1.5%